The amphiphilic peptide adenoregulin enhances agonist binding to A1-adenosine receptors and [35S]GTP gamma S to brain membranes.
1. Adenoregulin is an amphilic peptide isolated from skin mucus of the tree frog, Phyllomedusa bicolor. Synthetic adenoregulin enhanced the binding of agonists to several G-protein-coupled receptors in rat brain membranes. 2. The maximal enhancement of agonist binding, and in parentheses, the concentration of adenoregulin affording maximal enhancement were as follows: 60% (20 microM) for A1-adenosine receptors, 30% (100 microM) for A2a-adenosine receptors, 20% (2 microM) for alpha 2-adrenergic receptors, and 30% (10 microM) for 5HT1A receptors. High affinity agonist binding for A1-, alpha 2-, and 5HT1A-receptors was virtually abolished by GTP gamma S in the presence of adenoregulin, but was only partially abolished in its absence. Magnesium ions increased the binding of agonists to receptors and reduced the enhancement elicited by adenoregulin. 3. The effect of adenoregulin on binding of N6-cyclohexyladenosine ([3H]CHA) to A1-receptors was relatively slow and was irreversible. Adenoregulin increased the Bmax value for [3H]CHA binding sites, and the proportion of high affinity states, and slowed the rate of [3H]CHA dissociation. Binding of the A1-selective antagonist, [3H]DPCPX, was maximally enhanced by only 13% at 2 microM adenoregulin. Basal and A1-adenosine receptor-stimulated binding of [35S]GTP gamma S were maximally enhanced 45% and 23%, respectively, by 50 microM adenoregulin. In CHAPS-solubilized membranes from rat cortex, the binding of both [3H]CHA and [3H]DPCPX were enhanced by adenoregulin. Binding of [3H]CHA to membranes from DDT1 MF-2 cells was maximally enhanced 17% at 20 microM adenoregulin. In intact DDT1 MF-2 cells, 20 microM adenoregulin did not potentiate the inhibition of cyclic AMP accumulation mediated via the adenosine A1 receptor. 4. It is proposed that adenoregulin enhances agonist binding through a mechanism involving enhancement of guanyl nucleotide exchange at G-proteins, resulting in a conversion of receptors into a high affinity state complexed with guanyl nucleotide-free G-protein.
Moni
R W
RW
Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Romero
F S
FS
Daly
J W
JW
D000241:Adenosine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D029845:Amphibian Proteins; D000818:Animals; D023181:Antimicrobial Cationic Peptides; D001921:Brain / Q000166:cytology / Q000502:physiology / Q000648:ultrastructure; D002460:Cell Line / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism* / Q000648:ultrastructure; D000242:Cyclic AMP / Q000037:antagonists & inhibitors; D019204:GTP-Binding Proteins / Q000378:metabolism; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism / Q000494:pharmacology*; D007700:Kinetics; D015636:Magnesium Chloride / Q000494:pharmacology; D010455:Peptides / Q000502:physiology*; D058906:Purinergic P1 Receptor Agonists; D011898:Ranidae; D051381:Rats; D018047:Receptors, Purinergic P1 / Q000378:metabolism*; D012965:Sodium Chloride / Q000494:pharmacology; D013462:Sulfur Radioisotopes; D013876:Thiophenes / Q000494:pharmacology; D014316:Tritium; D014970:Xanthines / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D029845:Amphibian Proteins; D023181:Antimicrobial Cationic Peptides; D010455:Peptides; D058906:Purinergic P1 Receptor Agonists; D018047:Receptors, Purinergic P1; D013462:Sulfur Radioisotopes; D013876:Thiophenes; D014970:Xanthines; C485283:dermaseptin B2, Phyllomedusa bicolor; D015636:Magnesium Chloride; D014316:Tritium; C075004:PD 81723; C027513:N(6)-cyclohexyladenosine; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D012965:Sodium Chloride; C051360:1,3-dipropyl-8-cyclopentylxanthine; D000242:Cyclic AMP; D019204:GTP-Binding Proteins; D000241:Adenosine